Health

Advil Maker Haleon Said to Study Potential Deals to Bulk Up

Haleon weighs possible transactions for medium- to long-term
UK firm evaluates Sanofi’s $30 billion consumer health arm

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Dinesh Nair, Ruth David, and Sabah Meddings

January 31, 2023 at 2:02 PM UTC

Updated on

January 31, 2023 at 2:20 PM UTC

This article is for subscribers only.

Haleon Plc, the consumer health business spun out from British pharmaceutical producer GSK Plc, is in the early stages of studying large potential deals to bulk up its brand portfolio, people with knowledge of the matter said.

London-listed Haleon has been evaluating the merits of possible transactions for the medium- to long-term, including a combination with Sanofi’s $30 billion consumer-health arm, according to the people.